Drug Resistant Clinical Trials

58 recruitingLast updated: July 25, 2026

There are 58 actively recruiting drug resistant clinical trials across 17 countries. Studies span Not Applicable, Phase 2, Early Phase 1, Phase 1, Phase 3, Phase 4. Top locations include Hangzhou, Zhejiang, China, Beijing, Beijing Municipality, China, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Drug Resistant Trials at a Glance

58 actively recruiting trials for drug resistant are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Not Applicable with 28 trials, with the heaviest enrollment activity in Hangzhou, Beijing, and Boston. Lead sponsors running drug resistant studies include The Children's Hospital of Zhejiang University School of Medicine, Xuanwu Hospital, Beijing, and Assistance Publique Hopitaux De Marseille.

Browse drug resistant trials by phase

Treatments under study

About Drug Resistant Clinical Trials

Looking for clinical trials for Drug Resistant? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Drug Resistant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Drug Resistant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 58 trials

Recruiting
Not Applicable

Feasibility Study of the iVEAcare Neuromodulation System for the Treatment of Drug-Resistant Epilepsy

Drug Resistant Epilepsy
iVEAcare30 enrolled2 locationsNCT07640191
Recruiting
Not Applicable

Temporal Interference for Drug Resistant Epilepsy

Drug Resistant Epilepsy
Xuanwu Hospital, Beijing30 enrolled1 locationNCT06708143
Recruiting
Not Applicable

Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

EpilepsyDrug Resistant EpilepsyEpilepsy (Treatment Refractory)+4 more
University of California, San Francisco40 enrolled1 locationNCT07680842
Recruiting
Not Applicable

Biomarkers of Response to SEEG Thermocoagulation

Drug Resistant Epilepsy
Assistance Publique Hopitaux De Marseille45 enrolled1 locationNCT07399327
Recruiting
Not Applicable

Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial

Drug Resistant Epilepsy
Brigham and Women's Hospital10 enrolled1 locationNCT03868293
Recruiting
Not Applicable

Epileptogenic Network Visualisation With Advanced MRI

Drug Resistant Epilepsy
Cliniques universitaires Saint-Luc- Université Catholique de Louvain80 enrolled1 locationNCT06059157
Recruiting
Not Applicable

An Adaptive Randomized Controlled Trial

HIV InfectionsMulti Drug Resistant Tuberculosis
Columbia University360 enrolled1 locationNCT05633056
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting
Phase 4

Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment

Therapeutic Drug Monitoring (TDM)LinezolidTuberculosis Multi Drug Resistant Active
Marco Schiuma150 enrolled1 locationNCT07477119
Recruiting

Evaluate the effectiveness of personalised Deep Brain Stimulation

Drug Resistant Epilepsy
The Alfred20 enrolled1 locationACTRN12626000569303
Recruiting
Not Applicable

A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome

EpilepsyDravet SyndromeDrug Resistant Epilepsy+1 more
Hospices Civils de Lyon30 enrolled1 locationNCT07013331
Recruiting
Phase 2

Further MT for Antibiotic-Resistant Bacterial Colonization

Intestinal Multi-drug Resistant Organism Colonization
Emory University40 enrolled6 locationsNCT05835206
Recruiting
Not Applicable

Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis

Drug Resistant TuberculosisRifampin-resistant Tuberculosis
Albert Einstein College of Medicine280 enrolled1 locationNCT06590428
Recruiting
Phase 1Phase 2

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy

seizureEpilepsyDrug Resistant Epilepsy+2 more
NaviFUS Corporation8 enrolled3 locationsNCT06388707
Recruiting
Not Applicable

A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy

EpilepsyDrug Resistant EpilepsyEpilepsy, Temporal Lobe+1 more
NaviFUS Corporation16 enrolled1 locationNCT06492720
Recruiting
Not Applicable

MiCrobiota-gut-brain Axis in Resistant Epilepsy

EpilepsyDrug Resistant EpilepsyGut Microbiota
Niguarda Hospital120 enrolled1 locationNCT07010445
Recruiting
Early Phase 1

The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy

EpilepsyDrug Resistant
Xuanwu Hospital, Beijing5 enrolled1 locationNCT07095933
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting

Neurosurgical Outcome Network

DepressionTrigeminal NeuralgiaObsessive-Compulsive Disorder+20 more
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta4,500 enrolled27 locationsNCT06724029
Recruiting

Infection Risk Associated With Digestive MDRO Carriage in Hospitalized Patients

Multi Drug Resistant Organisms
Valeriu Gheorghita400 enrolled1 locationNCT07134270